Seng-ho Jeon
이 콘텐츠는 아직 번역되지 않았습니다.
Seng-ho Jeon is a Co-CEO of Daewoong Pharmaceutical. His relevance to the botulinum toxin industry comes from Daewoong leadership around the Nabota / Jeuveau product family and the company’s Korea-origin toxin expansion.
Jeon’s role helps separate product-origin leadership from commercial partner identity. Daewoong developed and manufactures the Nabota product family, while Evolus is the U.S. commercial company and label-holder context for Jeuveau.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Current organization | Daewoong Pharmaceutical |
| Current role | Co-CEO, as listed in Daewoong’s 2023 sustainability report |
| Industry relevance | Daewoong leadership for Nabota growth and global toxin expansion |
| Relevant companies | Daewoong Pharmaceutical and Evolus |
| Relevant brand | Jeuveau / Nabota |
| Market context | Korea-origin type A manufacturing, U.S. Jeuveau commercialization, and regional naming |
Career Notes
Section titled “Career Notes”- Daewoong’s 2023 sustainability report identifies Seng-ho Jeon as Co-CEO alongside Chang-jae Lee.
- The same report links Nabota to Daewoong’s 2022 sales growth and describes overseas growth as the botulinum toxin business expanded in the United States and elsewhere.
- Daewoong’s company history lists the 2014 Korean release of Nabota and the 2019 U.S. FDA approval of the company-developed botulinum toxin.
- Jeuveau’s U.S. prescribing information identifies the product as prabotulinumtoxinA-xvfs and keeps U.S. indication and unit language product-specific.
Nabota Expansion Context
Section titled “Nabota Expansion Context”Jeon matters because Daewoong is one of the clearest Korea-origin examples in the global aesthetic toxin market. Nabota, Jeuveau, and Nuceiva are related market identities, but they should not be treated as one universal label.
The leadership context is useful for market structure, not clinical ranking. Daewoong’s role as product-origin and manufacturing company does not make Jeuveau units interchangeable with Botox, Dysport, Xeomin, Daxxify, Letybo, or another toxin product.
Activity and Public Context
Section titled “Activity and Public Context”Jeon’s Daewoong and Jeuveau / Nabota relevance is company leadership during Nabota’s commercialization period, U.S. manufacturing context, and Korea-origin toxin expansion.